Zimmer Floats Divestments To Win European Approval Of Biomet Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Zimmer is negotiating with the European Commission on a strategic divestment strategy that would allow European anti-trust regulators to approve Zimmer’s pending acquisition of Biomet.
You may also be interested in...
Zimmer-Biomet Deal Clears EU Antitrust Review With Three Divestments
Zimmer and Biomet will drop some knee and elbow product lines to satisfy European regulator concerns over its planned $13.35 billion merger.
New Ortho Juggernaut: Zimmer Acquires Biomet For $13.35 Billion
Zimmer has agreed to buy Biomet by the first quarter of 2015, furthering the trend of consolidation in the $45 billion orthopedic device industry. The companies had combined revenues of $7.8 billion in 2013.
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: